EUVIMEDTutustu EUVIMEDiin
Open access

Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study

Maria A Lopez-Olivo iD, Maria E Suarez-Almazor iD, Gabrielle F Duhon iD, McKenna Cherry iD, Huifang Lu iD, Cassandra Calabrese iD, Mehmet Altan iD, Hussain Tawbi iD, Alexa Meara iD, Clifton O Bingham iD, Adi Diab iD, Viola B Leal iD and 1 more

JMIR Cancer · 2024

DOI: 10.2196/53443 ↗

At a glance

Journal article in JMIR Cancer, 2024. Written by Maria A Lopez-Olivo and 12 co-authors. Institution: Department of Health Services Research, MD Anderson Cancer Center, The University of Texas, Houston, TX, United States. Major MEDLINE topics: Neoplasms, Autoimmune Diseases, Immune Checkpoint Inhibitors, Patient Education as Topic. 33 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Background

Patients with cancer and an underlying autoimmune disease who are considering immune checkpoint blockers (ICBs) need to know about the benefits and risks of severe immune-related adverse events and flares of the autoimmune condition.

Objective

This study aims to develop and alpha test an educational website for patients with cancer.

Methods

Learning topics, images, and website architecture (including flow and requirements) were developed and iteratively reviewed by members of a community scientist program, a patient advisory group, and content experts. Alpha testing was performed, measuring the site’s usability using the Suitability Assessment of Materials and its acceptability using the Ottawa Acceptability Measure.

Results

The website included a home page; general information about ICBs; comprehensive modules on the benefits and risks of ICBs for patients with cancer and preexisting autoimmune diseases; general wellness information; and features such as a quiz, additional resources, and a glossary. For the alpha testing, 9 users assessed the newly developed website. Patient reviewers (n=5) had rheumatoid arthritis, Crohn disease, Sjogren syndrome, or vasculitis. Health care provider reviewers (n=4) were medical oncologists or rheumatologists. The median Suitability Assessment of Materials rating was 75 (IQR 70-79; range 0-100) for patients versus 66 (IQR 57-72; range 0-100) for providers (scores ≥70 indicate no substantial changes needed). Recommendations for improvement, mostly involving navigation and accessibility, were addressed. All participants expressed that the website was acceptable and balanced in terms of discussion of benefits and harms. Because half (2/4, 50%) of the providers suggested we increase the amount of information, we extended the content on the impact of having an autoimmune disease when considering ICB treatment, the probability of flares, and the management of flares in this context.

Conclusions

The feedback led to minor revisions to enhance readability, navigation, and accessibility, ensuring the website’s suitability as a decision-making aid. The newly developed website could become a supporting tool to facilitate patient-physician discussion regarding ICBs.

Subjects

MeSH terms (MEDLINE)

NeoplasmsAutoimmune DiseasesImmune Checkpoint InhibitorsPatient Education as TopicInternetHumansFemaleMaleMiddle Aged

Author keywords

Crohn diseaseSjogren syndromeacceptabilityadverse eventsarchitecturearthritisautoimmuneautoimmune diseasescancerdevelopmenteHealtheducationalhealth informationimmune checkpoint inhibitorsimmunology

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Department of Health Services Research, MD Anderson Cancer Center, The University of Texas, Houston, TX, United States.
  • Section of Rheumatology and Clinical Immunology of the Department of General Internal Medicine, MD Anderson Cancer Center, The University of Texas, Houston, TX, United States.
  • OCHIN, Inc, Portland, OR, United States.
  • Texas Woman's University, Houston, TX, United States.
  • Department of Rheumatologic & Immunologic Disease, Cleveland Clinic, Cleveland, TX, United States.
  • Department of Thoracic-Head & Neck Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, United States.

ORCID profiles: Maria A Lopez-Olivo, Maria E Suarez-Almazor, Gabrielle F Duhon, McKenna Cherry, Huifang Lu, Cassandra Calabrese, Mehmet Altan, Hussain Tawbi, Alexa Meara, Clifton O Bingham, Adi Diab, Viola B Leal, Robert J Volk

Funding

  • NCI NIH HHS

Cite

APA

Lopez-Olivo, M. A., Suarez-Almazor, M. E., Duhon, G. F., Cherry, M., Lu, H., Calabrese, C., Altan, M., Tawbi, H., Meara, A., Bingham, C. O., Diab, A., Leal, V. B., & Volk, R. J. (2024). Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study. JMIR Cancer. https://doi.org/10.2196/53443

Vancouver

Lopez-Olivo MA, Suarez-Almazor ME, Duhon GF, Cherry M, Lu H, Calabrese C, et al. Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study. JMIR Cancer. 2024. doi:10.2196/53443

BibTeX
@article{LopezOlivo2024,
  author = {Lopez-Olivo, Maria A and Suarez-Almazor, Maria E and Duhon, Gabrielle F and Cherry, McKenna and Lu, Huifang and Calabrese, Cassandra and Altan, Mehmet and Tawbi, Hussain and Meara, Alexa and Bingham, Clifton O and Diab, Adi and Leal, Viola B and Volk, Robert J},
  title = {Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study},
  journal = {JMIR Cancer},
  year = {2024},
  doi = {10.2196/53443}
}
Start for free →